Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide + cytarabine + dexamethasone + bortezomib in relapsed/refractory multiple myeloma after thalidomide
2006-002588-22Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, etoposide, cytarabine and dexamethasone in multiple myeloma (MM), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Started Jul 2007; status: completed.
02
Drugs
bortezomibetoposidecytarabinedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-002588-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002588-22.